Clinical pharmacology and challenges of targeting the MAPK pathway

Speaker: Jan Schellens

J. Schellens explores classes of drugs and biomarkers implicated in the MAPK pathway, its druggable and undraggable components and discovering biomarkers of efficacy as a way to select patients to achieve better response rates.

Discussion Points

  • Drugs and biomarkers targeting the MAPK pathway
  • KRAS, the undruggable protein
  • Improved therapy response rates thanks to patient selection